Quote of the Month

Karl Friston | 06/06/2020 | Quick Read

There is a pressing need for data that constrains our uncertainty about the current level of prevalent immunity. We need serological testing – not necessarily massively large-scale, but certainly sufficient to get a handle on how many people have had COVID-19 in the past few weeks. What proportion of people have had the infection and will have therefore a reduced probability of being reinfected? That’s an incredibly important unknown.

– Karl Friston, Wellcome Principal Research Fellow and Scientific Director at the Wellcome Trust Centre for Neuroimaging; Professor at the Institute of Neurology, University College London; and Honorary Consultant at the National Hospital for Neurology and Neurosurgery, London, UK

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Retina field I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Diagnostics Infectious disease

Karl Friston

Wellcome Principal Research Fellow and Scientific Director at the Wellcome Trust

Centre for Neuroimaging; Professor at the Institute of Neurology, University College London; and Honorary Consultant at the National Hospital for Neurology and Neurosurgery, London, UK.